Aju IB Investment Achieves 10x Return on Arcellx Biotech Exit
Aju IB Investment, a first-generation South Korean venture capital firm, achieved a 10-fold return on its investment in biotech company Arcellx, according to a report. The firm invested 17.4 billion KRW in Arcellx starting in 2019 through its Boston subsidiary Solasta Ventures and recovered 167.5 bi
GateMacroTradfiHub·08-26 23:03
